Alaunos Therapeutics
TCRT
130 hedge funds and large institutions have $184M invested in Alaunos Therapeutics in 2018 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 16 closing their positions.
8% more capital invested
Capital invested by funds: $170M → $184M (+$13.5M)
0.01% more ownership
Funds ownership: 0.26% → 0.27% (+0.01%)
2% less funds holding
Funds holding: 132 → 130 (-2)
12% less repeat investments, than reductions
Existing positions increased: 30 | Existing positions reduced: 34
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
62% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $3.13M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$1.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$1.47M |
| 3 |
D.E. Shaw & Co
New York
|
+$748K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$636K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$556K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Norges Bank
Oslo,
Norway
|
-$969K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$530K |
| 3 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$426K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$344K |
| 5 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$283K |
TCRT Hedge Fund Activity: Q3 2018 in Review
130 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2018, worth a combined $184M — up 7.9% from $170M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TCRT and 14 opened new positions — a net loss of 2 holders — while 34 trimmed existing stakes and 30 added.
The largest buyer was State Street, adding an estimated $1.7M. The largest seller was Norges Bank, cutting an estimated $969K.
- 130 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2018, down from 132 in Q2 2018.
- Funds reported $184M of Alaunos Therapeutics stock for Q3 2018, up 7.9% quarter-over-quarter.
- 14 funds opened new Alaunos Therapeutics positions in Q3 2018 and 16 closed out, a net change of -2 holders.
- The largest Alaunos Therapeutics buyer in Q3 2018 was State Street, an estimated $1.7M added.
- The largest Alaunos Therapeutics seller in Q3 2018 was Norges Bank, an estimated $969K sold.
Based on aggregated 13F filings for Q3 2018.